The effect of heparan sulphate on the crystallization of calcium oxalate in undiluted, ultrafiltered human urine

British Journal of Urology

Volumn 78, Issue 1, 1996, Pages 15-21

  Suzuki, K ^a   Ryall, R L ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Calcium oxalate crystallization; Crystal growth and aggregation; Heparan sulphate; Urine; Urolithiasis

Indexed keywords

CALCIUM OXALATE; HEPARAN SULFATE;

ADULT; ARTICLE; CRYSTALLIZATION; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; STONE FORMATION; ULTRAFILTRATION; URINE;

EID: 0030422894     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1996.00163.x     Document Type: Article

References (40)

1. Boyce W. Garvey FK. The amount and nature of the organic matrix in urinary calculi: a review. / Ural 1956; 76: 215-7
2. Nishio S. Abe Y. Wakatsuki A, Iwata H, Ochi K. Takeuchi M. Matsumoto A. Matrix glycosaminoglycan in urinary stones. / Urol 1985: 134: 503-5
3. Roberts SD, Resnick MI. Glycosaminoglycans content of stone matrix. / Urol 1986; 135: 1078-83
4. Yamaguchi S, Yoshioka T, Utsonomiya M et al. Heparan sulfate in the stone matrix and its inhibitory effect on calcium oxalate crystallization. Urol Res 1993; 21: 187-92
5. Goldberg JM, Cotlier E. Specific isolation and analysis of mucopolysaccharides (glycosaminoglycans) from human urine. Clin Chim Ada 1972: 41: 19-27
6. Wessier E. The nature of the non-ultraflltrable glycosaminoglycans of normal human urine. Biochem }1971: 122: 373-84
7. Suzuki K, Mayne K, Doyle IR, Ryall RL. Urinary glycosaminoglycans are selectively included into calcium oxalate crystals precipitated from whole human urine. Scanning Microscopy 1994: 8: 523-30
8. Iwata H, Kamei 0, Abe Y et al. The organic matrix of urinary uric acid crystals. / Urol 1988: 139: 607-10
9. Crawford JE, Crematy EP, Alexander AE. The effect of natural and synthetic polyelectrolytes on the crystallization of calcium oxalate. Aust ] Chem 1968; 21: 1067-72
10. Robertson WG, Peacock M, Nordin BEC. Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 1973: 43: 31-7
11. Bowyer RC. Brockis JG, McCulloch RK. Glycosaminoglycans as inhibitors of calcium oxalate crystal growth and aggregation. C/in Chim Acta 1979; 95: 23-8
12. Pak CYC. Holt K, Zerwekh JE. Attenuation by sodium urate of the inhibitory effect of glycosaminoglycans on calcium oxalate nucleation. Invest Urol 1979: 17: 138-40
13. Ryall RL. Harnett RM. Marshall VR. The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 1981; 112: 349-56
14. Fellström B, Danielson BG. Ljunghall S. Wikström B. Crystal inhibition: the effects of polyanions on calcium oxalate crystal growth. Clin Chim Acta 1986; 158: 229-35
15. Robertson WG, Scurr DS. Modifiers of calcium crystallization found in urine. I. Studies with a continuous crystallizcr using an artifical urine. / Ural 1986: 1 35: 1322-6
16. Scurr DS, Robertson WG. Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine. / Urol 1986: 1I6: 128-31
17. 7 Ryall RL. Harnett. RM. Hibherd C. Edyvane KA. Marshall VR. Effects of chondroitin sulphate, human serum albumin and Tamm-Horsfall mucoprotein on calcium oxalate crystallization in undiluted human urine. Urol Res 1991: 19: 181-8
18. Shum DKY. Gohel MU1. Separate effects of urinary chondroitin sulphate and heparan sulphate upon the crystallization of urinary calcium oxalate: differences between stone formers and normal controls. Clin Sei 1993: 85: 33-9
19. Ryall RL. Hibberd CM, Marshall VR. A method for studying inhibitory activity in whole urine. Urol Res 1985; 13: 285-9
20. Suzuki K. Miyazawa K, Tsugawa R. A simple method for determining the metastable limit of calcium oxalate. In Walker VR. Sutton RAL. Cameron ECB, Pak CYC. Robertson WG eds. Urolithiasis. New York: Plenum. 1989: 65-6
21. Kohri K. Garside J. Blacklock NJ. The effect of glycosaminoglycans on the crystallization of calcium oxalate. Br / Urol 1989: 63: 584-90
22. Norman RW, Scurr DS. Robertson WG. Peacock M. Inhibition of calcium oxalate crystallisation by pentosan polysulphate in control subjects and stone formers. Br ] Urol 1984: 56: 594-8
23. Martin X. Werness PG. Bergert JH. Smith LH. Pentosan polysulfate as an inhibitor of calcium oxalate crystal growth. / Uro/ 1984: 132: 786-8
24. Osswald H, Weinheimer G, Schutt I-D. Ernst W. Effective prevention of calcium-oxalate crystal formation in vitro and in vivo by pentosan polysulfate. In Walker VR. Sutton RAL, Cameron ECB. Pak CYC. Robertson WG eds. Urolithiasis. New York: Plenum. 1989: 141-4
25. Suzuki K. Miyazawa K, Tsugawa R. Inhibitory effect of sodium pentosan polysulfate on the formation, growth and aggregation of calcium oxalate in vitro. Jpn }Urol 1989: 80: 526-31
26. Cao LC. Boevé ER. Schröder FH, Robertson WG. Ketelaars GAM. De Bruijn. The effect of two new semi-synthetic glycosaminoglycans (G871. G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration. / Urol 1992: 147: 1643-6
27. Miyazawa K, Suzuki K, Tsugawa R. The quantitative study of inhibitory effect of pentosan polysulfate and chlorophyllin on the experimental calcium oxalate stone. Jpn ] Urol 1989; 80: 861-9
28. Sallis JD. Lumley MF. On the possible role of glycosaminoglycans as natural inhibitors of calcium oxalate stones. Invest Urol 1979: 16: 296-9
29. Koide T. Takemoto M. Itatani H. Takaha M. Sonoda T. Urinary macromoleculur substances as natural inhibitors of calcium oxalate crystal aggregation. Invest Urol 1981; 18: 382-6
30. Michelacci YM. Boim MA. Bergamaschi CT, Rovigatti RM. Schor N. Possible role l'or chondroitin sulfate in urolithiasis: in vivo studies in an experimental model, din Chim Acta 1992: 208: 1-8
31. Fellström B. Lindsjö M. Danielson BG. Karlsson FA. Ljunghall S. Binding of glycosaminoglycan inhibitors to calcium oxalate crystals in relation tu ionic strength, din Chim Acta 1989: 180: 213-20
32. Ryall RL. Darroch JN, Marshall VR. The evaluation of risk factors in male stone formers attending a general hospital out-patient clinic. Br / Urol 1984: 56: 1 16-21
33. 3 Samuell CT. A study of glycosaminoglycan excretion in normal and stone-forming subjects using a modified cetylpyridinium chloride technique, din Chim Acta 1981: 117: 63-73
34. Ryall RL. Stapleton AMF. Urinary macromolecules in calcium oxalate stone and crystal matrix: Good. bad. or indifferent? In Khan SR éd. Calcium Oxalate in Biological .Systems. Florida: CRC Press Inc. 1995: 265-90
35. Robertson VVG. Peacock M. Heyburn PJ. Marshall DU, Clark PB. Risk factors in calcium stone disease of the urinary tract, Rr ] Urol 1978: 50: 449-54
36. Nesse A. Garbossa G. Romero MC. Bogardo CE, Zanchetta Glycosaminoglyeans in urolithiasis. Xephron 1992: 62: 36-9
37. Baggio B. Gambaro G. Cicerello E et al. Urinary excretion of glycosaminoglycans in urological disease, din Riochem 1987: 20: 449-50
38. Caudarella R, Stefani F. Rizzoli R, Malavolta N. D'Antuono G. Preliminary results of glycosaminoglycans excretion in normal and stone forming subjects: Relationship with uricacid excretion. / Ural 1983: 129: 665-7
39. Hesse A. Wuzel H, Vahlensieck W. The excretion of glycosaminoglycans in the urine of calcium-oxalate-stone patients and healthy persons. Urol Int 1986: 41: 81-7
40. Newton I)}, Scott JE, Ahmad S. Orcadian rhythms and the urinary excretion of acid glycosaminoglycans in normal human adults. Conn Tissue Res 1979: 7: 47-55